-+ 0.00%
-+ 0.00%
-+ 0.00%

Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses

PUBT·09/04/2026 06:02:58
Listen to the news
Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses
  • Egetis flagged new clinical data for Emcitate in MCT8 deficiency, with presentations scheduled at ETA and ESPE in September 2026.
  • Updates will cover studies of early treatment, focusing on whether earlier use supports neurocognitive outcomes in young pediatric patients.
  • Separate results will address treatment withdrawal, assessing how patients fare when tiratricol is stopped.
  • The program underpins a US NDA under FDA Priority Review, with a September 28, 2026 decision date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.